title: Protection against advanced glycation end products and oxidative stress during the development of diabetic keratopathy by KIOM-79.
abstract: OBJECTIVE
  KIOM-79 is a mixture of 80% ethanol extracts of parched Puerariae radix, gingered Magnoliae cortex, Glycyrrhizae radix and Euphorbiae radix. The preventive effect of KIOM-79 on the development of diabetic keratopathy has been investigated.
  
  
  METHODS
  Seven-week-old male Zucker diabetic fatty (ZDF) rats were treated with KIOM-79 (50 mg/kg body weight) once a day orally for 13 weeks. The thickness of the cornea was measured and the extent of corneal cell death was detected by a terminal deoxynucleotidyl transferase dUTP nick-end labelling assay. The expression of advanced glycation end products (AGEs), 8-hydroxydeoxyguanosine, nuclear factor-kappaB (NF-κB), Bax and Bcl-2 were evaluated in corneal tissues.
  
  
  RESULTS
  The administration of KIOM-79 prevented corneal oedema and apoptotic cell death of corneal cells. The accumulation of AGE in corneal tissues was reduced in ZDF rats treated with KIOM-79. Moreover, KIOM-79 attenuated oxidative DNA damage, NF-κB activation and Bax overexpression in the cornea.
  
  
  CONCLUSIONS
  The results suggested that KIOM-79 exhibited corneal protective properties by not only reducing oxidative stress but inhibiting the AGEs/NF-κB downstream signal pathway during the development of diabetic keratopathy.
authors.affiliation: Diabetic Complications Research Center, Division of Traditional Korean Medicine (TKM) Integrated Research, Korea Institute of Oriental Medicine, Daejeon, South Korea.
authors.forename: Junghyun
authors.initials: J
authors.lastname: Kim
authors.forename: Chan-Sik
authors.initials: CS
authors.lastname: Kim
authors.forename: Hyojun
authors.initials: H
authors.lastname: Kim
authors.forename: Il-Ha
authors.initials: IH
authors.lastname: Jeong
authors.forename: Eunjin
authors.initials: E
authors.lastname: Sohn
authors.forename: Jin Sook
authors.initials: JS
authors.lastname: Kim
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001786:Blood Glucose / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects; D003315:Cornea / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000378:metabolism; D048909:Diabetes Complications / Q000517:prevention & control*; D004487:Edema / Q000517:prevention & control; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D008297:Male; D016328:NF-kappa B / Q000096:biosynthesis; D018384:Oxidative Stress / Q000187:drug effects*; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D051381:Rats; D011924:Rats, Zucker; D015398:Signal Transduction / Q000187:drug effects; D051028:bcl-2-Associated X Protein / Q000096:biosynthesis
chemical_list: D000975:Antioxidants; D001786:Blood Glucose; D017127:Glycation End Products, Advanced; C517978:KIOM 79; D016328:NF-kappa B; D010936:Plant Extracts; D019253:Proto-Oncogene Proteins c-bcl-2; D051028:bcl-2-Associated X Protein; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine